Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
Authors
Keywords
-
Journal
Cancer Medicine
Volume 2, Issue 2, Pages 234-242
Publisher
Wiley
Online
2013-03-07
DOI
10.1002/cam4.71
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303.
- (2017) A. B. Nixon et al. JOURNAL OF CLINICAL ONCOLOGY
- Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
- (2017) A. J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
- (2011) A. J. Zurita et al. ANNALS OF ONCOLOGY
- A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer
- (2011) Nan Soon Wong et al. Clinical Colorectal Cancer
- Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?
- (2011) Tina Cascone et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers of Anti-Angiogenic Therapy in Metastatic Colorectal Cancer (mCRC): Original Data and Review of the Literature
- (2011) M. Pohl et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
- (2010) V Goede et al. BRITISH JOURNAL OF CANCER
- Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
- (2009) N Murukesh et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
- (2009) L. Xu et al. CANCER RESEARCH
- Pathways mediating VEGF-independent tumor angiogenesis
- (2009) Napoleone Ferrara CYTOKINE & GROWTH FACTOR REVIEWS
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- VEGF-A Stimulates ADAM17-Dependent Shedding of VEGFR2 and Crosstalk Between VEGFR2 and ERK Signaling
- (2008) Steven Swendeman et al. CIRCULATION RESEARCH
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started